Expansion opportunities Exagen has demonstrated revenue growth and active investor communications with 2026 guidance and a record Q1, indicating a scalable business model and potential for expanding sales of AVISE testing across more rheumatology clinics and payers.

Strategic partnerships Partnerships with Johns Hopkins and biopharma/payers highlight a track record of collaborative validation and reimbursement discussions, suggesting opportunity to propose co-development, biomarker validation studies, and expanded coverage for CB-CAPS, T Cell markers, and anti-PAD4/anti-RA33 tests.

Clinical leadership Leadership additions in 2025, including a new CSO and board members, reinforce a strong R&D and clinical validation focus, enabling sales conversations around cutting-edge lupus and RA diagnostics and potential integration into clinical guidelines.

Global and regional scaling Recent facility expansion commitments and regional growth signals indicate readiness to support increased testing volume, international collaboration, and regional payer engagements, opening routes for provincial/nederal health system contracts and multi-site deployments.

Data driven value Exagen’s AVISE platform combines multiple modalities and validated algorithms, supporting value-based selling aimed at earlier diagnoses and improved patient outcomes, with upsell potential for comprehensive diagnostic panels and longitudinal monitoring.